Generic and biosimilar specialist Sandoz is strengthening its footprint in Slovenia, pledging $440 million to set up a new biosimilar facility for sterile product manufacturing some 24 miles from ...

Novartis' soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen's blockbuster osteoporosis therapy Prolia (denosumab), clearing the way for regulatory ...